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1. Introduction 
Epithelial ovarian cancer is sensitive to chemotherapy and approximately 75% of patients 
achieve complete clinical remission after the initial treatment. However, most develop a 
recurrence which results in death after a chronic course. Therefore, most patients are 
candidates for second-line chemotherapy, including approximately 20% among of these 
patients with platinum- and taxane-resistant disease. Patients with platinum-and taxane-
resistant disease have poor outcomes, and most would like to prolong their survival with 
relieved symptoms and the best possible quality of life (QOL). The effects of several drugs 
which are being used for these purposes are similar, but it is usually difficult to relieve 
recurrent disease with one drug. Monotherapy has been generally chosen for having the 
most favorable toxicity profile in patients with platinum- and taxane-resistant disease. 
However, it is not clear whether this strategy is optimal with the various novel anticancer 
drugs and targeted agents under development. In this article, pegylated liposomal 
doxorubicin (PLD), which is used worldwide, and irinotecan, the predominant agent in 
Japan for the treatment of platinum- and taxane-resistant ovarian cancer, are evaluated for 
their effects and toxicity in monotherapy and in combination at lower doses with other 
drugs. 
2. Objectives 
Platinum- and taxane-resistant epithelial ovarian cancer is not curable; therefore, patients 
give fully informed consent and are treated to maintain their QOL. The initial treatment 
aims to cure cancer while the second-line chemotherapy seeks palliation as the primary goal. 
To be specific, the aim is to balance toxicity and the beneficial effects, and considering the 
toxicities after the initial treatment and patient’s desires, more convenient and less toxic 
agents should be chosen. Second-line chemotherapy is intended to prevent deterioration of 
cancer lesions and to relieve symptoms.  
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3. Principle for choosing therapy 
In the treatment of recurrent ovarian cancer, the issues to consider are the treatment-free 
interval (TFI), toxicity continuously observed from the initial treatment, recurrent tumor 
diameter and increased CA125. The TFI is the most important for selecting regimens, and 
the longer the TFI, the higher the response rate (Figure 1).1,2) In selecting regimens, when the 
TFI is 6 months or longer, the tumor is considered to be sensitive to chemotherapy. In 
contrast, when the TFI is less than 6 months, the tumor is considered to be resistant to 
chemotherapy. For patients with a platinum- and taxane- resistant disease, a drug without 
cross-resistance to paclitaxel and carboplatin must be selected. On the other hand, 
recommended therapies for tumors sensitive to drugs, based on the results of randomized 
controlled trials and meta-analyses, are carboplatin- combination therapy with or without a 
targeted agent. However, 6-12 months of TFI is considered to be a gray zone (platinum-
resistant factor remains; partially sensitive) and more careful consideration should be 
needed in choosing regimens.  
 
 
Fig. 1. Principle for choosing therapy. 
Pegylated liposomal doxorubicin (PLD), topotecan, and weekly paclitaxel are the drugs 
approved by the Food and Drug Administration (FDA), and gemcitabine (GEM), oral 
etoposide, and docetaxel can also be used. In Japan, weekly irinotecan is frequently used. The 
effects of drugs on patients with platinum- and taxane-resistant disease are similar and no 
drug can complete the treatment in most patients. Based on the performance status (PS) and 
toxicity persisting from the initial treatment and the bone-marrow function of an individual 
patient, drugs to be administered should be presented to the patient. PLD is safer for heavily 
pretreated patients than topotecan and GEM due to mild bone-marrow toxicity, however, 
nonhematotoxity such as hand-foot syndrome (HFS), stomatitis and mucositis frequently 
develop, patient’s desire is considered, finally, the drugs are selected. 3) However, it is usually 
difficult to completely relieve cancer with one drug with high efficacy and low toxicity, and 
the drugs are therefore changed as required while assessing the effect and toxicity. 
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4. Effects and toxicities 
4.1 Effects 
The response rate of anticancer drugs in platinum-resistant ovarian cancer ranges from 12% 
to 32%, and the survival (median) is around 8–10 months. The effect of anticancer drugs is 
generally evaluated by the change in tumor diameter; i.e., if the tumor diameter increases, 
outcomes are judged to be progressive disease (PD) and the treatment is discontinued or 
changed, and if the tumor diameter decreases, the treatment is evaluated to be effective and 
continued if no toxicity-related problem occurs. However, it was shown in several studies 
that such direct evaluation results of tumor diameter do not always correlate with survival 
time. We investigated the relationship between the drug-induced change in tumor diameter 
and survival, albeit in a small-size population, and showed that there was no difference in 
the survival time between the patients with complete response (CR) or partial response (PR) 
and those with stable disease (SD), and that only patients with PD showed particularly poor 
outcomes (the IGCS Symposium, Edinburgh, 2004). Cesano et al. showed similar results. 4) 
Rose et al. recently analyzed outcomes of patients with platinum-resistant ovarian ovarian 
cancer who were enrolled in 11 GOG phase II clinical trials (1996–2004) and compared the 
survival time between the CR/PR, SD and PD groups (Figure 2). 5)  The results showed no 
difference between the CR/PR and the SD groups while the overall survival (OS) in the PD 
group was significantly poorer than that in the CR/PR/SD group (p<0.001). Given these 
corroborating results, it is important to evaluate the effect of treatment by the total percent 
of responders and patients with SD who have no increase in tumor size (disease control 
rate) in treatments of patients with platinum-resistant disease. This percent is expressed as 
the clinical benefit. Consequently, it is considered that patients with platinum- and taxane- 
resistant ovarian cancer who have tumors evaluable as SD as well as CR/PR are given 
effective treatment when patients have no toxicity problems and can maintain their QOL. 
 
 
 
 
Fig. 2. Survival by tumor response status (landmark analysis) 
Rose PG, et al. Gynecol Oncol. 2010;17:324-329 
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4.2 Toxicity 
The toxicity depends on agents but generally tends to increase with the frequency of 
chemotherapy. Therefore, in the treatment of platinum- and taxane- resistant ovarian cancer, 
much attention should be given to the occurrence of toxicities. Topotecan, GEM, docetaxel 
are highly hemotoxic, and patients using PLD, irinotecan, or weekly paclitaxel should be 
monitored for non-hemotoxic events that reduce the QOL. There is concern about HFS 
occurring in treatment with PLD, diarrhea with irinotecan, and peripheral neuropathy and 
arthralgia during weekly paclitaxel therapy. When a patient is treated with irinotecan, 
diarrhea is frequently induced, therefore, informed consent for determination of UGT1A1 
polymorphism should be obtained from the patient and the assay is carried out as needed. 6,7) 
5. Pgylated liposomal doxorubicin (PLD) 
PLD was approved in 1999 by the FDA and in 2000 by the European Medicines Evaluation 
Agency as treatment for chemorefractory and chemoresistant epithelial ovarian cancer and 
has been used as the first option for patients with chemorefractory and chemoresistant 
epithelial ovarian cancer over the world.  
5.1 Efficacy 
The results of phase II/III studies of PLD showed response rates to platinum-resistant 
disease ranging from 8.7% to 31.4%, SD rates from 18.2% to 51.3% and a high clinical benefit 
around 60%, and no difference in the efficacy between 50 and 40 mg/m2 of PLD. A phase II 
study has recently been completed in Japan and the response rate for recurrent platinum-
resistant ovarian cancer was 21.0%, the SD rate was 40.3% and the clinical benefit was 61.3%, 
which was similar to those in the studies in Europe and the United States. 8-15) 
5.2 Safety 
The data in Europe and the United States show that PLD is accompanied by a low incidence 
and low severity of hematotoxicities such as neutropenia. The incidence of neutropenia of 
grade 3/4 ranges from 10% to 20%, and granulocyte colony stimulating factor (G-CSF) 
drugs are seldom needed. The incidence of thrombopenia is lower. On the other hand, PLD 
is accompanied by high incidences of subjective non-hematotoxities including HFS and 
stomatitis at FDA-approved doses and schedules. HFS and stomatitis developed in 
approximately 40% of patients; however, HFS of grade 2 or higher were found in 19.8% to 
31.5% of patients treated with PLD at a dose of 50 mg/m2 and 2.8% to 15.5% (less than half 
as frequently) at doses of 40 mg/m2 and less. Stomatitis of grade 2 or higher developed in 
14% to 38% or more of patients treated with PLD at a dose of 50 mg/m2 and in 8.0% of those 
treated with 40 mg/m2. 8-15) We showed the efficacy of cooling the wrists and ankles during 
infusion to prevent HFS (ESMO, Milan, 2010). We are currently conducting a clinical trial of 
stomatitis prevention.  
Based on the review of previous studies, no difference in the efficacy between 50 and 40 
mg/m2 of PLD, therefore, a dose of 40 mg/m2 is preferable for patients with platinum-
resistant disease to reduce adverse events. To scientifically confirm the dosage, the Japanese 
Gynecologic Oncology Group (JGOG) has started a randomized comparative study of 50 
and 40 mg/m2 of PLD in patients with platinum-and taxane- resistant ovarian cancer (TFI < 
6 months). 
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5.3 Japanese-specific toxicity 
The incidences and severity of PLD-induced toxicity in the Japanese population are different 
from those in European and the United States populations. In a Phase II trial in Japan, the 
incidence of HFS was 78% (Grade 2 or more: 51%) and that of neutropenia of grade 3 or 
more was 68%, suggesting the necessity of toxicity monitoring and treatment. 16) 
5.4 Comparison with other drugs in Phase III trials 
 Topotecan: The response rate of topotecan was around 14% in patients with platinum- 
and taxane-resistant ovarian cancer. In a phase III comparative study with paclitaxel, 
the response rate of topotecan was 13.3% in the platinum-resistant ovarian cancer 
group, better than paclitaxel’s rate of 6.7%.17) The time to progression in the topotecan 
group was significantly better than that in the paclitaxel group; consequently, topotecan 
was confirmed to have at least an equivalent effect to paclitaxel. In comparison with 
PLD, topotecan had a tendency of being more effective in terms of the progression free 
survival (PFS) and overall survival (OS) in the platinum-resistant ovarian cancer group; 
on the other hand, PLD was significantly more effective than topotecan in the platinum-
sensitive ovarian cancer group (Table 1). 18)  
 
 
Table 1. Survival of Randomized studies. 
 Gemcitabine: The response rate at doses of 800-1,000 mg/m2/week and the schedule of 
days 1, 8 and 15 and one-week withdrawal was 13-14% in the platinum-resistant 
ovarian cancer group. Mutch et al. conducted a phase III comparative study with 
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gemcitabine (GEM) that showed no significant differences in PFS and OS between PLD 
and GEM. 14)  Ferrandina et al. reported no differences in PFS between PLD and GEM in 
relapsed patients with a treatment-free interval (TFI) of 12 months or less, but a 
significant efficacy in OS with PLD compared to GEM (Table 1). 15) From the results of 
the above phase III studies, PLD was considered to have similar efficacy as other novel 
drugs on platinum-resistant disease; however, it was more effective at improving the 
survival rate in patients with recurrent ovarian cancer, including platinum-sensitive 
cancer, than other drugs. 
 Difference in toxicity: The results of phase III comparative studies with topotecan or 
GEM confirmed that HFS and stomatitis significantly developed in patients treated 
with 50 mg/m2 of PLD while the incidence of HFS was slightly higher in patients 
treated with 40 mg/m2 of PLD compared with those treated with GEM and no 
difference was found in the incidence of stomatitis between PLD and GEM. On the 
other hand, PLD induced hematotoxicity less than topotecan and gemcitabine. 
Although neutropenia of grade 3 or more developed in 10% to 20% of patients treated 
with 50 mg/m2 of PLD, febrile neutropenia was rarely found. The incidence of 
thrombocytopenia was further less. 13-15) 
5.5 Combination with other drugs 
In multidrug therapy, toxicity is often increased by the combination of multiple drugs at doses 
recommended for monotherapy. In contrast to initial chemotherapy, which aims to cure 
cancer, second-line chemotherapy aims to combine drugs at lower doses, considering the 
toxicity based on the results of phase I clinical studies. In particular, drugs with non-
hematotoxicity such as PLD should be used in accordance with the above consideration. 3) In 
fact, in phase II clinical trials, the incidence and severity of PLD-specific non-hematotoxicities 
(HFS, stomatitis) were reduced without loss of efficacy when PLD was administered at lower 
doses in combination with GEM, topotecan, vinorelbine, and oxaliplatin. 
In vitro data suggested a potential synergistic interaction between PLD and GEM. 19) 
Combination chemotherapy of PLD and GEM achieved good response rates ranging from 
22% to 33%, however, the clinical benefit was between 28% and 61%, which was similar to 
PLD monotherapy. 20-23) As for hematotoxicity, neutropenia of grade 3/4 was slightly higher 
and HFS of grade 2/3 was slightly less. The combination of PLD and GEM is an active and 
acceptably tolerated option in the treatment of patients with platinum-resistant ovarian 
cancer (Table 2). The combination at the dosages chosen seems suitable for this patient 
population. Synergism between PLD and topotecan was demonstrated in platinum-resistant 
disease. 24) A median total response rate of 28% and clinical benefit of 72% were 
demonstrated, with a median TTP of 30+weeks in the combination of PLD and topotecan for 
platinum-resistant disease (Table 3).25) These data compare favorably to the data of both the 
drugs administered as single agent. In comparison of two studies of combination 
chemotherapy of PLD and oxaliplatin, the response rates for platinum-resistant disease were 
28.6% and 38.5% and the clinical benefit was 71.4% and 76.9%, suggesting the higher 
efficacy compared with PLD monotherapy. 26,27) Furthermore, the response rates for 
platinum-sensitive disease were 66.7% and 81.5% and the clinical benefit was 82.8% and 
100%, showing the efficacy similar or more to other platinum combination chemotherapy 
(Table 3). The incidence of HFS was low and no marked increase in hematotoxicity was 
found, consequently, it was considered to be controllable. Consequently, PLD, with its low 
hematotoxicity but specific non-hematotoxicities, is recommended for use not as a 
monotherapy but in low-doses combinations for improved patient QOL. 
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Table 2. Phase II studies of PLD + GEM inpatients with platinum-resistant disease. 
 
 
Table 3. Phase II studies of PLD-combination in platinum- and taxane-pretreated patients. 
6. Irinotecan 
Irinotecan has achieved a response rate of 23.6% in recurrent ovarian cancer. 28) 
Irinotecan/cisplatin combination chemotherapy has shown a response rate of 33% in 
platinum-resistant ovarian cancer, 29) and 76% when used as the initial regimen for epithelial 
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ovarian cancer. 30) Regarding dose-limiting toxicity, although neutropenia and diarrhea were 
observed, diarrhea was thought to cause no remarkable problems in the combination 
regimen examined. Based on these results, irinitecan is considered to be useful drug in 
chemotherapy for ovarian cancer. There were two phase II studies of single agent of 
irinotecan for platinum- and taxane-resistant ovarian cancer. Matsumoto et al. treated 28 
patients with platinum- and taxane-resistant or refractory ovarian cancer with irinotecan 
(irinotecan 100mg/m2, days 1,8,15, every 4 weeks), and they observed a response rate of 
28.5% with a SD rate of 32.1%, and the clinical benefit was obtained in 60.7% of the patients. 
31) Grade3 or 4 neutropenia and diarrhea were shown in 17.9% and 10.7% of the patients, 
respectively. They concluded that the weekly dosing schedule of irinotecan seems to be 
effective and safe salvage chemotherapy regimen for platinum- and taxane-resisitant or 
refractory epithelial ovarian cancer. There are few studies of irinotecan, commonly used in 
Japan for second-line chemotherapy, from Europe and the United States. Bodurka et al. 
conducted a clinical trial of irinotecan at a dose of 300 mg/m2 every 3 weeks in 31 platinum-
resistant and platinum-refractory patients. 32) The response rate was 17% and lower than that 
Matsumoto et al. reported; however, irinotecan had at least an equivalent effect to topotecan 
and GEM. Furthermore, 14 (48%) patients had stable disease (SD) and 65% showed a clinical 
benefit, which was similar to the result of Matsumoto et al. There are no data directly 
comparing irinotecan and topotecan, which have similar active mechanism; however, in a 
comparison between the results of a phase II study in Japanese patients with recurrent 
ovarian cancer (topotecan: 1.2 mg/m2, days 1–5, every 3 weeks), 33) the results of Matsumoto 
et al. (irinotecan: 100 mg/m2, days 1, 8 and 15, every 4 weeks), 31) and the results of Bodurka 
et al. (irinotecan: 300 mg/m2, every 3 weeks), 32) toxicities markedly differed. The incidences 
of hematotoxicity of grade 3 or more were higher in the topotecan group; i.e., the incidence 
of neutropenia of grade 3 or more was 95.8% in the topotecan group, but 17.9% and 35.5% in 
the irinotecan groups of Matsumoto et al. and Bodurka et al., respectively. Furthermore, 
thrombopenia occurred in 97% of the topotecan group, but rarely in the irinotecan groups 
(0% and 6.5% in studies of Matsumoto et al. and Bodurka et al., respectively). Diarrhea 
frequently occurred in the irinotecan groups with ≥grade 3 incidences of 10.7% and 32.3% in 
Matsumoto et al. and Bodurka et al., respectively. On the other hand, the incidence in the 
topotecan group was low (7.1%). As shown above, in treatment with topotecan and 
irinotecan for patients with recurrent ovarian cancer, hematotoxicity and diarrhea should be 
monitored, respectively.  
6.1 Combination with cisplatin 
The synergism between irinotecan and cisplatin, 34) the different mechanism of action 
between the two drugs, 35) some lack of cross-resistance, 36) and the relative absence of 
overlapping principal toxicities support the rationale behind considering combination 
therapy with these agents. Minagwa et al. reported that in cisplatin-resistant Hela cells 
cisplatin showed a collateral sensitivity to SN-38, an active metabolite of irinotecan. 37) 
Furthermore, isobologram analysis indicated synergistic interaction of cisplatin and SN-38 
for cisplatin-resistant Hela cells. Based on the results of a phase I study, our group 
conducted a phase II study with irinotecan and cisplatin. 29) Twenty-five patients with 
recurrent ovarian cancer who had previously undergone platinum-based combination 
chemotherapy received this treatment consisting of 50 or 60mg/m2 of irinotecan on days 1, 
8, and 15, and 50 or 60mg/m2 of cisplatin on day1 every 4 weeks administrated 
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intravenously. The overall response rate was 40%.  Even when the analysis was limited to 21 
platinum-resistant cases, the response rate was 33.3% with a stable disease (SD) rate of 
38.1%, and the clinical benefit was obtained in 15/21 (71.4%) patients (Table 4). Neutropenia 
occurred in 54.5% of cycles and 64% of patients. Although diarrhea was observed in 31.8% 
of the courses, there were only a few severe cases (3.0%), and this condition could be 
managed with the administration of loperamide and/or Kanpo medicine along with  
adequate hydration. Irinotecan/cisplatin represented a useful doublet regimen for 
platinum-resistant disease because high clinical benefit was shown, and irinotecan may 
induce relatively mild hematologic toxicity, particularly, thrombocytopenia, compared with 
topotecan. Neutropenia was reserved by short-term G-CSF. Although diarrhea frequently 
occurs during irinitecan monotherapy, it is no longer thought to be a serious toxicity in 
combination chemotherapy due to irinotecan dose reduction. 
 
 
Table 4. Phase II studies of irinotecan-combinations in patients with platinum-resistant 
disease. 
6.2 Combination with oral etoposide 
Etoposide, a topoisomerase-II inhibitor, has high antitumor activity against various animal 
and human malignancies. The efficacy of etoposide may be regimen-dependent, since 
prolonged oral administration has yielded better results than intravenous administration. 
The largest study to date, performed by the Gynecologic Oncology Group (GOG), reported a 
response rate of 8.3%.38) Rose et al. gave oral etoposide (50mg/kg of body weight) from days 
1 to 21 every 4 weeks to 41 patients with platinum–resistant or 25 patients with platinum-
/taxane-resistant ovarian cancer and obtained response rates of 26.8% and 32%, 
respectively. 39)  
DNA topoisomerase-I and –II are nuclear enzymes that participate in various genetic 
processes, including transcription, replication, recombination and chromosome segregation 
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at mitosis. 40) These two DNA topoisomerases are functionally related and act in concert. 
Both seem to be essential for maintaining cell viability throughout the cell cycle. 
Topoisomerase-I treatment induces an increase in the S-phase cell population with an 
increase in topoisomerase-II mRNA expression. Thus, topoisomerase-I can modulate 
topoisomerase-II levels to enhance the effect of topoisomerase-II inhibitors. 41,42) Therefore, 
combined use of topoisomerase-I and-II targeting agents could theoretically inhibit both 
DNA and RNA synthesis completely, resulting in synergistic cytotoxicity.  
We undertook a pilot study and a phase II study to evaluate the antitumor efficacy and 
toxicity of a combination of irinotecan and oral etoposide in women with platinum- and 
taxane-resistant ovarian cancer. 43,44)  In both studies, irinotecan was administered in an 
intravenous dose of 60 or 70mg/m2 as a 90-min infusion on days 1 and 15 of a 28-day cycle, 
and etoposide was administered in an oral dose of 50mg/body on days 1 to 21. The two 
studies showed very similar results for efficacy (according to the RECIST and CA125 
criteria) and toxicity (Table 4). A pilot study of irinotecan and oral etoposide in platinum- 
and taxane-resistant ovarian cancer reported an overall response rate of 44.4% in 
12/27cases, and the median duration of response was 11 months. 43)  Adding 11 patients 
with SD, a high clinical benefit was shown in 23/27 cases (85.1%). The median time to 
progression and the median survival in the study group as a whole was 9 months and 17 
months, respectively. The major toxicity was neutropenia (grade 3/4, 59%), but was 
managed easily by administration of short-term G-CSF. Febrile neutropenia was observed in 
only one patient. Diarrhea was infrequent and mild. The other study was conducted in the 
northern area of Japan (Tohoku Gynecologic Cancer Unit).44) Forty-two patients with 
recurrent epithelial ovarian cancer who had previously undergone platinum-based 
combination chemotherapy were registered in this study, and the overall response rate was 
50.0%. Even when the analysis was limited to 31 platinum-resistant cases, a response rate of 
41.9% and clinical benefit of 77.4% were achieved. As for toxicity, grade 3/4 neutropenia 
was observed in 22 patients (52.4%) and febrile neutropenia in 3 patients (7.1%). Grade 3/4 
diarrhea occurred in only two patients (4.8%). Acute myeloid leukemia (AML) developed as 
a secondary malignancy in one patient in each study. Topoisomerase-II-related AML, 
initially noted as a therapy-related complication of childhood leukemia, is characterized by 
the lack of a myelodysplastic phase, no dysplastic change in diagnostic bone marrow 
specimens, balanced chromosomal translocations involving 11q23, and variable 
chemosensitivity. This leukemia is characteristically related to the cumulative dose of 
etoposide and has a shorter latency period (median, 24 to 30 months) than the AML 
associated with alkylating agent therapy. In general, a total dose of etoposide of more than 
6g may be associated with an increased risk of developing leukemia. The total dose of 
etoposide received by the two patients who had AML in the two studies was 10.5g and 
14.2g, respectively. We strongly recommended that this regimen not be given for more than 
6 cycles, even if the response or stable disease is sustained. These results of the two studies 
justify further studies of irinotecan plus oral etoposide in patients with platinum- and 
taxane-resistant epithelial ovarian cancer. 
7. Conclusions 
In the treatment of platinum- and taxane- resistant recurrent ovarian cancer, monotherapy is 
recommended from the perspective of toxicity. However, monotherapy of PLD and 
irinotecan, which have specific non-hematotoxicities, increases the incidence and severity of 
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HFS, stomatitis and diarrhea, resulting in a decreased patient QOL. We investigated 
whether combination therapy of these drugs with other drugs would exploit their 
advantages at lower doses. The results of studies of combination therapy of PLD or 
irinotecan showed lower incidences of the non-hematotoxicities specific to these drugs at the 
same time good patient QOL was maintained; furthermore, a good clinical benefit was 
shown without loss of the effect in comparison with that of monotherapy. In conclusion, we 
propose the use of combination therapy using PLD or irinotecan in the treatment of 
platinum- and taxane- resistant recurrent ovarian cancer. 
8. Summary 
In the treatment of platinum- and taxane-resistant recurrent cancer, monotherapy is 
recommended as the standard treatment from the perspective of toxicity. However, 
pegylated liposomal doxorubicin (PLD) and irinotecan have specific non-hematotoxicities 
that impair the quality of life (QOL) of patients; therefore, combination therapy at lower 
doses may provide better clinical benefit than monotherapy, especially as it can be 
maintained for a longer time because the lowering of the doses decreases the specific 
toxicities.  
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